This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05403/identifier/chemspider/
n7http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB05403/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05403/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05403
rdf:type
n3:Drug
n3:description
CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.
n3:generalReferences
# Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW: CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem. 2001 May;77(3):849-63. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11331414
n3:group
investigational
n3:indication
Investigated for use/treatment in asthma and parkinson's disease.
owl:sameAs
n7:DB05403
dcterms:title
CEP-1347
adms:identifier
n9:133005 n10:117379 n11:DB05403
n3:mechanismOfAction
CEP-1347, an orally active molecule, is a selective and potent inhibitor of the stress-activated protein kinase pathway, an intracellular signaling pathway that is an essential component of the stress response leading to neuronal death. In-vitro cell culture systems and in-vivo mouse and non-human primate models of Parkinson's disease have shown that CEP-1347 protects dopamine neurons in the substantia nigra, the area of the brain affected by Parkinson's disease.
n3:IUPAC-Name
n4:271B42C0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B42C6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B42C5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B42C2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B42C3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B42C4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B42BE-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B42BC-363D-11E5-9242-09173F13E4C5 n4:271B42BF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B42BD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B42CC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B42CD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B42C7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B42C8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B42CA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B42C9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B42CB-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B42D2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B42D4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B42D5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B42D1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B42D0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B42D3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B42C1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B42CE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B42CF-363D-11E5-9242-09173F13E4C5